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Since the use of postoperative concomitant and adjuvant TMZ with radiotherapy as the standard therapy for glioblastoma, the 2-year survival rate of glioblastoma patients has improved from 10.9% to 27.2%. 2, 3 Methylation of the O 6 -methylguanine-DNA-methyltranferase (MGMT) promoter, the most common MGMT silencing mechanism, is the strongest predictor for the benefit from TMZ chemotherapy and patients' outcome. Nearly half of the patients with MGMT-methylated glioblastoma survived more than 2 years. 3, 4 MGMT genetic changes, 5, 6 histone modifications, 7, 8 p53 derangement, 9, 10 and posttranscriptional regulation 11, 12 also lead to MGMT silencing. MicroRNAs (miRNAs) regulate a variety of cellular processes, including cell differentiation, cell proliferation, apoptosis, stress resistance, and stem cell maintenance. 13, 14 Recently, several miRNAs were reported to be associated with posttranscriptional regulation of MGMT and with the clinical outcome of glioblastoma patients. Overexpression of miR-125b was associated with resistance to TMZ and, as a result, a shorter overall survival. 15 Two studies have shown that miR-181d downregulated MGMT mRNA and protein expression in glioblastoma cell lines, and higher expression of miR-181d was associated with lower MGMT level and longer patient survival. 16, 17 A cell study revealed that miR-221 and miR-222 downregulated MGMT levels and led to increased TMZinduced apoptosis and reduced cell viability. 18 Expression of miR-224 was reported to have a radiation sensitizing effect on glioblastoma cell lines, and an analysis of the Cancer Genome Atlas (TCGA) data revealed that lower miR-224 expression levels in male patients were correlated with poorer survival. 19 Some of these previous studies were performed on a relatively small number of samples, and some significant prognostic factors for glioblastoma, for example age, gender, Karnofsky performance status (KPS), extent of resection, isocitrate dehydrogenase 1 (IDH1) status, TMZ treatment, and bevacizumab treatment, were not adjusted in their evaluation. 15, 16, 18 The aims of this study were to analyze the expression of five MGMT-and prognosis-associated miRNAs (miR-125b, miR-181d, miR-221, miR-222, and miR-224) in glioblastomas, as well as to examine their relationship with MGMT promoter methylation status and patients' prognosis.
Materials and Methods

Patients and Samples
The study protocol was approved by the Institutional Review Board of Taipei Veterans General Hospital (2015-04-007BCF). General data of the patients, including age, gender, KPS, date of surgery, extent of resection, and history of radiotherapy and medication were retrieved from their medical records. One hundred and fourteen patients with newly diagnosed primary glioblastoma who had received postoperative TMZ chemotherapy with concomitant radiotherapy and had follow-up for more than 1 month were included in the study. The original histopathology slides were reviewed to confirm the diagnosis. The specimens were formalin fixed and paraffin embedded. Tumor areas were selected for miRNA expression analysis. The results of the immunohistochemical staining for R132H-mutant IDH1 and the MGMT methylation-specific polymerase chain reaction analyzing the methylation status of MGMT promoter were from our previous study. 20 For IDH status, immunostaining using R132H-mutant IDH1 specific antibody (clone H09, dilution 1:100; Dianova, Hamburg, Germany) was performed. IDH1/2 sequencing was done in IDH1 R132H immunonegative cases who were younger than 55 years of age, and did not find any additional IDH mutation. Samples with methylation-specific PCR products of any intensity were regarded as a positive result. Survival time of the patients was measured from the date of surgery to the date of death or to the date of last follow-up (for censored patients). The characteristics of study cases are listed in Supplementary Table 1 (all supplemental materials can be found at American Journal of Clinical Pathology online). The data and samples were analyzed anonymously after a coding procedure.
Real-Time Quantitative RT-PCR of miRNA
Real-time quantitative RT-PCR (qRT-PCR) was used to determine the levels of five miRNAs: miR125b-5p, miR-181d-3p, miR-221-3p, miR-222-3p, and miR-224-5p, and miR-186-5p was selected to be the reference according to manufacturer's recommendations. The sequences of target miRNAs are listed in Supplementary  Table 2 . Total RNA was extracted from formalin-fixed, paraffin-embedded tumor tissues using a miRNeasy FFPE Kit (Qiagen, Germantown, MD) according to the manufacturer's instructions. Assays to quantify miRNAs were performed using Taqman advanced miRNA probes (Applied Biosystems) according to the manufacturer's instructions. Briefly, 20 ng of total RNA was reverse transcribed to cDNA using a TaqMan Advanced miRNA cDNA Synthesis Kit (Applied Biosystems, Foster City, CA). The 20-μL real-time PCR reaction included 5 μL of diluted reverse transcription product, 1 × TaqMan universal PCR master mix, and 1 μL primers and probe mix of the TaqMan advanced miRNA assay kit. Reactions were incubated in a 96-well optical plate at 95°C for 5 minutes, followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute. PCR reactions were run on a StepOne Plus real-time PCR machine (Applied Biosystems). The average cycle threshold (CT) value of each miRNA from three nonneoplastic brains was used as control. The amount of miRNA relative to the nonneoplastic brain control was calculated by the 2 −△△CT method, in which △△CT = (CT miRNA -CT miR-186-5p ) target -(CT miRNA -CT miR-186-5p ) control . The 2 −△△CT value greater than 1.0 was defined as upregulation.
Statistical Analysis
The Fisher exact test was used to compare the distribution of categorical variables. Differences in continuous variables were compared using the Mann-Whitney or Kruskal-Wallis test. Survival curves were plotted using the Kaplan-Meier method, and their differences were calculated with the log-rank test. A Cox regression model was used to adjust the influence of age, gender, KPS, extent of resection, bevacizumab treatment, IDH1 status, and MGMT promoter methylation status. The difference was considered statistically significant when the P value was less than .05. 
Results
Expression Levels of miRNAs and MGMT Promoter Methylation
There was upregulation of expression of miR125b-5p, miR-181d-3p, miR-221-3p, miR-222-3p, and miR-224-5p in 13.2%, 5.3 %, 12.3%, 32.5%, and 78.9% of the glioblastomas, respectively. Forty-three (37.3%) of the tumors had more than one (24.6% two, 7.0% three, 6.1% four) upregulated miRNAs. The expression levels of these five miRNAs were not significantly different between MGMT promoter methylated tumors and unmethylated tumors ❚Table 1❚.
Expression of miRNAs and Survival
The correlations between the patients' survival and the expression of miRNAs are listed in ❚Table 2❚. In the glioblastomas without MGMT promoter methylation, miR-125-5b and miR-221-3p each had a significantly negative prognostic association, and there was a similar but borderline significant association of upregulation of miR181d-3p with poorer survival (P = .054). The associations of poor prognosis with expression of miR-125b-5p, miR181d-3p, and miR-221-3p were significant in the multivariate (Cox) analysis ❚Table 3❚. Upregulation of miR-125b-5p, miR-181d-3p, or miR-221-3p was noted in 26 tumors, nine with upregulation of two of these (eight tumors with miR-125b-5p and miR-221-3p, and one tumor with miR125b-5p and miR-181d-3p). The survival of patients whose tumors had two upregulated miRNAs was not different from that of those with one (hazard ratio, 1.002; P = .997). Upregulation of any of these three miRNAs was associated with shorter survival (median, 13.3 months) compared to those that had downregulated or unchanged miRNAs (median, 20.2 months) ❚Figure 1❚.
Discussion
In this study, we demonstrated that the expression levels of miR-125b-5p, miR-181d-3p, miR-221-3p, miR-222-3p, and miR-224-5p were not significantly related to the status of MGMT promoter methylation. Increased expression of miR-125b-5p, miR-181d-3p, or miR-221-3p was associated with shorter survival of patients with MGMT-unmethylated glioblastomas. This is similar to the results of a previous report, which included 45 glioma patients and showed that higher miR-125b, miR-221, or miR-222 expression was associated with poorer prognosis. 21 Another study of 40 glioblastoma patients treated with TMZ revealed that eight patients with upregulated miR-125b had significantly shorter overall survival. 15 On the other hand, miR-181d-5p has been reported to suppress MGMT expression, 17 and it was correlated with a better survival of glioblastoma patients. 16 In the present study, the expression level of miR-181d-3p was not correlated with the status of MGMT promoter methylation. However, as the case numbers with upregulated miR181d-3p was small, it might be insufficient to make a solid conclusion. Further studies including more such cases are needed to clarify the impact of miR-181d-3p and miR181d-5p on glioblastoma.
Our study confirmed the prognostic role of miR125b-5p, miR-181d-3p, and miR-221-3p in a larger cohort, and further demonstrated that their association with poor prognosis was mainly observed in the MGMTunmethylated group. The reason for the above observation is unclear. We hypothesized that the intrinsic effects of these miRNAs could be more evident when the natural course of disease is less altered by TMZ chemotherapy in the MGMT-unmethylated glioblastomas.
miR-125b, which has been reported to be an oncogene in glioblastoma cells, 22 contributes to the progression of glioblastoma by promoting cell proliferation, inhibiting cell apoptosis, and increasing chemoresistance. As an oncogene, it promotes cell proliferation and inhibits cell apoptosis by targeting Bmf (Bcl2 modifying factor) 22 ; it protects cells from apoptosis and promotes tumorigenesis by targeting TP53INP1 (tumor protein p53 inducible nuclear protein 1) 23 ; and it suppresses the proliferation of glioma stem cell by targeting E2F2 and LIN28. 24, 25 Upregulation of miR-125b increases NF-κB activity and TMZ resistance of glioblastoma cells by targeting the negative NF-κB regulator TNFAIP3, 15, 26 while downregulation of miR-125b increases the sensitivity of glioblastoma cells to TMZ. 27 Furthermore, miR-125b has been reported to inhibit paclitaxel-induced cytotoxicity in breast cancer cell lines by targeting BAK1 (BCL2 antagonist/killer 1), leading to an increased chemoresistance. .366
miR-181d-3p 1.00 (1.00-1.00)
1.00 (1.00-1.00)
. MiR-221 has been shown to have a pro-oncogenic effect in gliomas in previous studies: it induced tumor progression, migration, survival, and resistance to TMZ in glioma cell lines. The proposed targets of miR-221 included p27, PUMA, Cx43, DNM3, and the Akt pathway. [29] [30] [31] [32] On the other hand, Quintavalle et al 18 found that miR-221 downregulated MGMT expression and increased TMZ sensitivity by targeting MGMT in glioblastoma cell lines. However, the expected survival benefit from miR-221 expression was not observed in their study, which showed that miR-221 was upregulated in 11 short-survival glioblastoma patients and downregulated in four long-survival ones. 18 It is therefore speculated that the pro-oncogenic effect of miR-221 is more powerful than its TMZ sensitizing effect.
MiR-181d belongs to the miR-181 family, which can have both oncogenic and tumor suppressor effects depending on the cancer types. MiR-181d has been shown to act as a tumor suppressor by targeting K-ras and Bcl-2 in gliomas. 33 The study by Zhang et al 16 demonstrated that miR-181d downregulated MGMT in glioblastoma cell lines by directly targeting MGMT, and higher expression of miR-181d was correlated with better overall survival in a cohort of 29 glioblastoma patients treated with TMZ. However, this relationship was not statistically significant in the validation using the TCGA dataset. Also, some important prognostic factors, such as the IDH1 mutation status and MGMT promoter methylation status were not addressed. In contrast to the report by Zhang et al, 16 our result showed that upregulation of miR-181d-3p was correlated with shorter overall survival in MGMTunmethylated glioblastomas after adjustment for other prognostic factors. Although limited by the small number of glioblastoma cases with upregulated miR-181d-3p, this observation could suggest that miR-181d might also have oncogenic effects contributing to poorer prognosis. In a study of hepatocellular carcinoma, miR-181d was shown to promote cancer cell migration by targeting MAPK phosphatase 5 and resulting in p38 MAPK activation. 34 It is likely that miR-181d has similar effects in gliomas. ❚Figure 1❚ Survival curves stratified by the expression level of microRNAs (miRNAs). In cases with upregulation of any of miR-125b-5p, miR-181d-3p, and miR-221-3p lived shorter than those with downregulated or unchanged miRNAs. P = .011. Although miR-222 and miR-224 had been shown to be prognosis-related in glioblastomas, 19, 35 they showed no significant prognostic impact in the present study. The study by Cheng et al 35 identified miR-222 to be significantly associated with shorter overall survival in MGMT-methylated glioblastomas; our results showed no significant association between miR-222 expression level and survival in both the MGMT methylated and unmethylated groups. The correlation of low miR-224 expression and poorer survival in male glioblastoma patients reported by a previous study 19 was not observed in our study either.
In conclusion, the present study identified miR125b-5p, miR-181d-3p, and miR-221-3p as potential prognostic biomarkers in MGMT-unmethylated glioblastomas, and showed that the upregulation of any of these three miRNAs predicted a poor prognosis.
